Retatrutide
A triple-agonist product profile interacting with GLP-1, GIP and glucagon receptors, presented around appetite, blood sugar and fat-burning pathways.
Three-receptor product profile
The page organizes the stated triple-agonist mechanism into a clear, premium product presentation.
Retatrutide represents a major breakthrough in weight loss journeys. Unlike earlier treatments like Wegovy or Mounjaro, which focus on one or two hormone receptors, Retatrutide targets three.
This makes it a triple agonist, interacting with the following receptors to promote fat burning, blood sugar control, and appetite reduction:
- GLP-1 (Glucagon-like peptide 1)
- GIP (Glucose-dependent insulinotropic polypeptide)
- GCG (Glucagon)
GLP-1 pathway
The product description identifies glucagon-like peptide-1 as one of the three targeted receptors.
GIP pathway
Glucose-dependent insulinotropic polypeptide is presented as the second receptor pathway.
Glucagon pathway
Glucagon completes the stated three-receptor agonist profile.
Verify your product
Enter the serial number exactly as it appears on the original packaging.